Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $20.88 million. The enterprise value is -$30.40 million.

Market Cap	20.88M
Enterprise Value	-30.40M

Important Dates

The next estimated earnings date is Tuesday, May 13, 2025, before market open.

Earnings Date	May 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 62.15 million shares outstanding. The number of shares has increased by 10.34% in one year.

Current Share Class	62.15M
Shares Outstanding	62.15M
Shares Change (YoY)	+10.34%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	39.52%
Float	49.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.34
P/TBV Ratio	0.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.42.

Current Ratio	4.07
Quick Ratio	3.96
Debt / Equity	0.42
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -75.07% and return on invested capital (ROIC) is -36.31%.

Return on Equity (ROE)	-75.07%
Return on Assets (ROA)	-32.20%
Return on Invested Capital (ROIC)	-36.31%
Return on Capital Employed (ROCE)	-78.47%
Revenue Per Employee	n/a
Profits Per Employee	-$1.08M
Employee Count	60
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.53% in the last 52 weeks. The beta is 1.59, so Passage Bio's price volatility has been higher than the market average.

Beta (5Y)	1.59
52-Week Price Change	-70.53%
50-Day Moving Average	0.44
200-Day Moving Average	0.64
Relative Strength Index (RSI)	41.07
Average Volume (20 Days)	193,947

Short Selling Information

The latest short interest is 1.75 million, so 2.81% of the outstanding shares have been sold short.

Short Interest	1.75M
Short Previous Month	1.69M
Short % of Shares Out	2.81%
Short % of Float	3.57%
Short Ratio (days to cover)	9.20

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-65.17M
Pretax Income	-76.57M
Net Income	-64.77M
EBITDA	-62.09M
EBIT	-65.17M
Earnings Per Share (EPS)	-$1.07

Full Income Statement

Balance Sheet

The company has $76.76 million in cash and $25.48 million in debt, giving a net cash position of $51.28 million or $0.83 per share.

Cash & Cash Equivalents	76.76M
Total Debt	25.48M
Net Cash	51.28M
Net Cash Per Share	$0.83
Equity (Book Value)	61.26M
Book Value Per Share	0.99
Working Capital	59.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$47.96 million and capital expenditures -$34,000, giving a free cash flow of -$47.99 million.

Operating Cash Flow	-47.96M
Capital Expenditures	-34,000
Free Cash Flow	-47.99M
FCF Per Share	-$0.77

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.34%
Shareholder Yield	-10.34%
Earnings Yield	-310.16%
FCF Yield	-229.82%

Analyst Forecast

The average price target for Passage Bio is $7.67, which is 2,182.74% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.67
Price Target Difference	2,182.74%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1